Press releases
- Calliditas Announces Submission of New Drug Application to U.S. FDA for Nefecon in Patients with Primary IgA Nephropathy
- Calliditas strengthens its US Commercial and Medical Affairs Organization
- Calliditas Therapeutics to Host Key Opinion Leader Perspectives Webinar on the Pathophysiology and Treatment of IgA Nephropathy in Clinical Practice
Year-end report 2020
On February 18, 2021, at 07:00 CET, Calliditas Therapeutics published its year-end report for 2020.